目的 探究羟氯喹联合他克莫司软膏治疗面部激素依赖性皮炎的临床疗效。方法 选取2013年3月—2014年9月襄阳市中心医院皮肤科门诊收治的面部激素依赖性皮炎患者73例,随机分为对照组(36例)和治疗组(37例)。两组患者皆外用0.1%他克莫司软膏于患处,2次/d。对照组口服盐酸左西替利嗪片,5 mg/次,1次/d。治疗组口服硫酸羟氯喹片,0.2 g/次,2次/d。两组均连续治疗4周。观察两组的临床疗效,同时比较两组的反跳发生率。结果 治疗后,对照组和治疗组的总有效率分别为80.56%、100.00%,两组比较差异具有统计学意义(P <0.05)。治疗后,两组症状总评分均较治疗前显著下降,同组治疗前后差异有统计学意义(P <0.05);且治疗组的下降程度优于对照组,两组比较差异有统计学意义(P <0.05)。对照组和治疗组反跳发生率分别为5.56%、0,两组比较差异具有统计学意义(P <0.05)。结论 羟氯喹联合他克莫司软膏治疗面部激素依赖性皮炎具有较好的临床疗效,且反跳发生率低,具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of hydroxychloroquine combined with Tacrolimus Ointment in treatment of facial hormone dependent dermatitis. Methods Patients (73 cases) with facial hormone dependent dermatitis in dermatology outpatient service of Xiangyang Centre Hospital from March 2013 to September 2014 were randomly divided into control (n= 36) and treatment (n= 37) groups. Patients in two groups were external used 0.1% Tacrolimus Ointment in the affected area, twice daily. The patients in the control group were po administered with Levocetirizine Hydrochloride Tablets, 5 mg/time, once daily. The patients in the treatment group were po administered with Hydroxychloroquine Sulfate Tablets, 0.2 g/time, twice daily. Two groups were treated for four weeks. After treatment, the efficacy was evaluated, and the bounce rate in two groups was compared. Result After treatment, the efficacies in the control and treatment groups were 80.56% and 100.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, symptoms total score in two groups were significant reduced, and the difference was statistically significant in the same group (P < 0.05). And the reducing degree in treatment group was better than that in the control group, with significant differences between two groups (P < 0.05). The bounce rate in the control and treatment groups were 5.56% and 0, respectively, and there were differences between two groups (P < 0.05). Conclusion Hydroxychloroquine combined with Tacrolimus Ointment has good clinical efficacy in treatment of facial hormone dependent dermatitis with low bounce rate, which has a certain clinical application value.